The Week in Review: Most Promising Technology Awards at ChinaBio® Partnering Forum

At the recent ChinaBio® Partnering Forum, three scientists were selected to receive ChinaBio’s Most Promising Technology Award, based on their novel life science research; Hutchison China MediTech is forming a Chinese infant formula JV with Hain Celestial Group; the Institute of Biophysics, a division of CAS, announced a neuroimaging collaboration with the University of Pennsylvania; Sinovac Biotech reported positive results from a Phase I trial of its vaccine for Hand, Foot, and Mouth Disease; Sinocom Pharma, soon to IPO, announced a 21% increase in revenues and 13% rise in net income; Hainan Honz Pharma said its first half net income will fall 50% after the SFDA prohibited use of its drug in children under 12; Q1 earnings reports are showing higher revenues for China life science enterprises listed in the US, though net income isn’t keeping up; and BeiGene, Ltd. has hired seasoned veterans to head Clinical Research and Regulatory Affairs for its portfolio of oncology drugs. More details…. Stock Symbols: (AIM: CHM) (NSDQ: HAIN) (NSDQ: SVA) (SHE: 300086) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});